Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1

Metastatic castration‐resistant prostate cancer (mCRPC) is a lethal form of treatment‐resistant prostate cancer and poses significant therapeutic challenges. Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EMBO Mol Med
Auteurs principaux: Patel, Rachana, Fleming, Janis, Mui, Ernest, Loveridge, Carolyn, Repiscak, Peter, Blomme, Arnaud, Harle, Victoria, Salji, Mark, Ahmad, Imran, Teo, Katy, Hamdy, Freddie C, Hedley, Ann, van den Broek, Niels, Mackay, Gillian, Edwards, Joanne, Sansom, Owen J, Leung, Hing Y
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5887544/
https://ncbi.nlm.nih.gov/pubmed/29540470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708347
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires